Palvella Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 28, 2026, 7:30 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedPalvella Therapeutics Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations, PDUFA Date February 28, 2027
8-KAug. 4, 2026, 7:30 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits